X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (667) 667
Newspaper Article (411) 411
Patent (238) 238
Publication (110) 110
Magazine Article (53) 53
Book / eBook (51) 51
Trade Publication Article (36) 36
Dissertation (22) 22
Book Review (11) 11
Book Chapter (6) 6
Reference (6) 6
Conference Proceeding (3) 3
Report (2) 2
Streaming Audio (2) 2
Web Resource (2) 2
Newsletter (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (259) 259
index medicus (213) 213
female (174) 174
male (174) 174
human necessities (164) 164
hygiene (164) 164
medical or veterinary science (163) 163
chemistry (119) 119
metallurgy (119) 119
preparations for medical, dental, or toilet purposes (107) 107
peptides (106) 106
organic chemistry (104) 104
middle aged (94) 94
general tagging of cross-sectional technologies spanning over several sections of the ipc (87) 87
general tagging of new technological developments (87) 87
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (87) 87
microbiology (86) 86
aged (85) 85
beer (84) 84
biochemistry (84) 84
enzymology (84) 84
mutation or genetic engineering (84) 84
spirits (84) 84
vinegar (84) 84
wine (84) 84
culture media (83) 83
compositions thereof (82) 82
microorganisms or enzymes (82) 82
propagating, preserving or maintaining microorganisms (82) 82
performing operations (81) 81
transporting (81) 81
research (79) 79
technical subjects covered by former uspc (79) 79
adult (75) 75
specific therapeutic activity of chemical compounds ormedicinal preparations (75) 75
article (66) 66
medical and health sciences (66) 66
medicin och hälsovetenskap (66) 66
oncology (62) 62
textiles (60) 60
paper (57) 57
bandages, dressings or absorbent pads (55) 55
devices providing patency to, or preventing collapsing of,tubular structures of the body, e.g. stents (55) 55
filters implantable into blood vessels (55) 55
first-aid kits (55) 55
fomentation (55) 55
orthopaedic, nursing or contraceptive devices (55) 55
prostheses (55) 55
treatment or protection of eyes or ears (55) 55
care and treatment (54) 54
risk factors (54) 54
layered products (52) 52
layered products, i.e. products built-up of strata of flat ornon-flat, e.g. cellular or honeycomb, form (52) 52
physics (52) 52
technical subjects covered by former us classification (51) 51
cancer (47) 47
treatment outcome (47) 47
adolescent (46) 46
clinical medicine (44) 44
child (43) 43
united states (42) 42
urology & nephrology (42) 42
klinisk medicin (41) 41
testing (41) 41
measuring (39) 39
analysis (38) 38
pediatrics (38) 38
abridged index medicus (37) 37
health aspects (37) 37
investigating or analysing materials by determining theirchemical or physical properties (37) 37
risk (37) 37
technical subjects covered by former uspc cross-reference artcollections [xracs] and digests (37) 37
braiding (36) 36
cotton-wool (36) 36
fabrics made by such processes or apparatus, e.g. felts,non-woven fabrics (36) 36
knitting (36) 36
lace-making (36) 36
making textile fabrics, e.g. from fibres or filamentarymaterial (36) 36
non-woven fabrics (36) 36
trimmings (36) 36
wadding (36) 36
studies (35) 35
animals (34) 34
children (34) 34
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (34) 34
clinical trials (33) 33
diabetes (32) 32
prognosis (32) 32
therapy (32) 32
child, preschool (30) 30
carcinoma, renal cell - drug therapy (28) 28
kidney neoplasms - drug therapy (28) 28
after-treatment of the shaped products, e.g. repairing (27) 27
follow-up studies (27) 27
prospective studies (27) 27
shaping of material in a plastic state, not otherwise providedfor (27) 27
shaping or joining of plastics (27) 27
working of plastics (27) 27
working of substances in a plastic state, in general (27) 27
antineoplastic agents - therapeutic use (26) 26
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (23) 23
Collection Dvlpm't (Acquisitions) - Vendor file (8) 8
UTL at Downsview - May be requested (6) 6
UofT at Scarborough - Stacks (5) 5
UofT at Mississauga - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
OISE - Stacks (3) 3
Earth Sciences (Noranda) - Stacks (2) 2
Engineering & Comp. Sci. - Stacks (2) 2
Gerstein Science - Stacks (2) 2
Trinity College (John W Graham) - Stacks (2) 2
Art - Library use only (1) 1
Criminology - Stacks (1) 1
Earth Sciences (Noranda) - Reference (1) 1
Faculty of Information - May be requested in 6-10 wks (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
Media Commons - Audio Visual (1) 1
Media Commons - Microtexts (1) 1
Music - Stacks (1) 1
OISE - Curriculum Resources (1) 1
OISE - Ontario Historical Ed (1) 1
OISE - Storage (1) 1
Online Resources - Online (1) 1
Regis College - Stacks (1) 1
Royal Ontario Museum - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's College (John M. Kelly) - Rare Book (1) 1
Trinity College (John W Graham) - Storage (1) 1
Victoria University E.J. Pratt - Coleridge (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1410) 1410
French (126) 126
German (53) 53
Spanish (19) 19
Chinese (18) 18
Portuguese (15) 15
Korean (6) 6
Danish (3) 3
Hungarian (2) 2
Japanese (2) 2
Greek (1) 1
Norwegian (1) 1
Russian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10019, pp. 661 - 670
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 293 - 300
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 76 - 86
Summary Background Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | PLUS CISPLATIN | METAANALYSIS | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | DOXORUBICIN | METHOTREXATE | VINBLASTINE | CANCER | GEMCITABINE | Lymph Node Excision | Cystectomy - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Male | Vinblastine - administration & dosage | Cystectomy - adverse effects | Urothelium - pathology | Cisplatin - administration & dosage | Time Factors | Urinary Bladder Neoplasms - pathology | Female | Chemotherapy, Adjuvant | Carcinoma - pathology | Doxorubicin - administration & dosage | Carcinoma - drug therapy | Urinary Bladder Neoplasms - mortality | Drug Administration Schedule | Time-to-Treatment | Carcinoma - surgery | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Urinary Bladder Neoplasms - surgery | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Methotrexate - administration & dosage | Urothelium - surgery | Neoplasm Staging | Urothelium - drug effects | Deoxycytidine - analogs & derivatives | Care and treatment | Chemotherapy | Carcinoma | Hospitals | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 26, pp. 2457 - 2466
Journal Article
by Speliotes, Elizabeth and Willer, Cristen and Berndt, Sonja and Monda, Keri and Thorleifsson, Gudmar and Jackson, Anne and Allen, H.L and Lindgren, Cecilia and Luan, J and Mägi, Reedik and Randall, Joshua and Vedantam, Sailaja and Winkler, Thomas and Qi, Lu and Workalemahu, Tsegaselassie and Heid, Iris and Steinthorsdottir, Valgerdur and Stringham, Heather and Wheeler, Eleanor and Wood, Anew and Ferreira, Teresa and Weyant, Robert and Segrè, Ayellet and Eestrada, Karol and Liang, Liming and Nemesh, James and Park, J.H and Gustafsson, Stefan and Kilpeläinen, Tuomas and Yang, Joanna and Bouatia-Naji, Nabila and Eesko, Tõnu and Feitosa, Mary Furlan and Kutalik, Zoltán and Mangino, Massimo and Raychaudhuri, Soumya and Scherag, Ane and Smith, Albert Vernon and Welch, Ryan and Zhao, Jing Hua and Aben, Katja and Absher, Devin and Amin, Najaf and Dixon, Anna and Fisher, Eeva and Glazer, Nicole and Goddard, Michael and Heard-Costa, Nancy and Hoesel, Volker and Hottenga, Jouke Jan and Johansson, Åsa and Johnson, Toby and Ketkar, Shamika and Lamina, Claudia and Li, Shengxu and Moffatt, Miriam and Myers, Richard and Narisu, Narisu and Perry, John and Peters, Marjolein and Preuss, Michael and Ripatti, Samuli and Rivadeneira Ramirez, Fernando and Sandholt, Camilla and Scott, Laura and Timpson, Nicholas and Tyrer, Jonathan and Wingerden, Sophie and White, Charles and Wiklund, Freik and Barlassina, Christina and Chasman, Daniel and Cooper, Matthew and Jansson, J.O and Lawrence, Robert and Pellikka, Niina and Prokopenko, Inga and Shi, Jianxin and Thiering, Eelisabeth and Alavere, Helene and Alibrandi, Maria and Almgren, Peter and Arnold, Alice and Aspelund, Thor and Atwood, Larry and Balkau, Beverley and Balmforth, Anthony and Bennett, Amanda and Ben-Shlomo, Y and Bergman, Richard and Bergmann, Sven and Biebermann, Heike and Blakemore, Alexana and Boes, Tanja and Bonnycastle, Lori and Bornstein, Stefan and Brown, Morris and Buchanan, Thomas and Busonero, F and Campbell, Harry and ... and MAGIC and Procardis Consortium and on behalf of Procardis Consortium and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Institutionen för genetik och patologi and Uppsala universitet
Nature Genetics, ISSN 1061-4036, 11/2010, Volume 42, Issue 11, pp. 937 - 948
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 06/2012, Volume 13, Issue 9, pp. 1323 - 1336
Introduction: Over the past decade, a greater understanding into the molecular pathogenesis of renal cell carcinoma (RCC) has led to major advances in... 
sunitinib | renal cell carcinoma | VEGF-targeted therapy | VEGF pathway | Sunitinib | Renal cell carcinoma | EFFICACY | PLUS INTERFERON-ALPHA | ANTITUMOR-ACTIVITY | SORAFENIB | PHASE-III TRIAL | I TRIAL | DOUBLE-BLIND | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | FACTOR-TARGETED THERAPY | ENDOTHELIAL GROWTH-FACTOR | Pyrroles - pharmacokinetics | Humans | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - metabolism | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Indoles - administration & dosage | Angiogenesis Inhibitors - administration & dosage | Receptors, Vascular Endothelial Growth Factor - metabolism | Pyrroles - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Chemotherapy, Adjuvant | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | Treatment Outcome | Angiogenesis Inhibitors - pharmacokinetics | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Protein Kinase Inhibitors - administration & dosage | Animals | Indoles - adverse effects | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Indoles - pharmacokinetics | Indoles - therapeutic use | Kidney Neoplasms - pathology | Kidney Neoplasms - drug therapy
Journal Article